Robert J. Bitterman, Director at RXi Pharmaceuticals Corp (RXII), bought 500 shares at $3.90 ($2K) on 2013-08-26, disclosed to the SEC on 2013-08-27.
Open-market purchase of $2k RXII by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| PHIO | BUY | 2026-01-02 | $5K | — | Filing → |
| PHIO | BUY | 2025-12-29 | $5K | — | Filing → |
| PHIO | BUY | 2025-11-24 | $6K | — | Filing → |